Biotech

The Schall Law Firm and Roche Freedman LLP announced today that they have filed a securities class action lawsuit on behalf of plaintiff Carl D. Cachia against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU ) and certain of its officers. The class action, filed in the Southern District of New York, captioned Cachia v. BELLUS Health Inc., et. al. , and docketed under Case No. 1:21-cv-02278, is on behalf of a class consisting of investors who purchased or otherwise acquired BELLUS securities between September 5, 2019 and July 5, 2020, inclusive (the ''Class Period''). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased BELLUS securities during the Class Period, you have until May 17, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. If you are a shareholder who suffered a loss, click here to participate .

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com , or by email at brian@schallfirm.com .

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

BELLUS is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough (one that lasts over eight weeks) and other afferent hypersensitization-related disorders. The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about BELLUS's business, operations, drug products, drug product development, competition, and present and future business prospects. Specifically, Defendants misrepresented and/or failed to disclose that BLU-5937's "high selectivity" contributed to the drug potentially being less efficacious and thus likely unable to meet the primary endpoint of the Company's Phase 2 study. As a result, when Defendants announced before markets opened on July 6, 2020, that BLU-5937 had failed the Phase 2 study, the Company's stock price plummeted over 75% on heavy trading volume.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

News Provided by Business Wire via QuoteMedia

Boosh Plant-Based Brands Corporate Update

Boosh Plant-Based Brands Corporate Update

Boosh Plant-Based Brands Inc.(CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector, provides the following corporate update.

  • Boosh lists products with additional distributor in Canada to reach more retailers. Horizon Grocery + Wellness is Western Canada's leading distributor of organic and natural foods, and nutritional health supplements. Horizon is the supplier of major natural, grocery and independent grocery chains, independent natural health stores, buying clubs, restaurants, cafes, and specialty retailers. Boosh will also utilize the services of their subsidiary, PSC Natural Foods natural and organic food distributor serving Vancouver Island and the Lower Mainland.
  • Boosh Plant-Based Brand's newest Line, Amuse Boosh, is currently shipping Nationwide. Amuse offers a delectable selection of fine vegan cheese and pate that is sure to please any discerning palate.
  • Boosh Mac n Cheese Shelf Stable product just listed at Georgia Main (24 IGA and 5 Fresh St Markets)
  • Sales update
  • Boosh has secured a lease for Head Quarters at # 205- 18428 53 Ave Surrey BC with Warehouse and Office space. Previous lease ends Aug 31, 2022. New Lease is in newer building and represents over 60% cost savings. (Previous lease and overhead was $156,889.00 annually and new one is $59,992.00)
  • Nobu Mano joins Boosh as Controller and brings 17 years in accounting with CPA, CA designation since 2009. Nobu has worked within the Food and Manufacturing industry for over 6 years and has audit experience in food companies, and manufacturing companies. His wealth of knowledge is well-suited for the company.
  • The Company is providing this bi-weekly update on the status of the management cease trade order granted on August 2, 2022 (the "MCTO") by its principal regulator, the British Columbia Securities Commission under National Policy 12-203 -Management Cease Trade Orders ("NP 12-203"), following the Company's announcement on August 2, 2022 (the "Default Announcement") that it was unable to file its audited annual financial statements for the year ended March 31, 2022, and accompanying management's discussion and analysis, annual information form and related certifications (collectively, the "Documents") on or before August 2, 2022, as required under applicable securities laws. The MCTO does not affect the ability of investors who are not insiders to trade in the securities of the Company.

The Company reports that: (i) there are no changes to the information contained in the bi-weekly status updated dated August 2, 2022, that would reasonably be expected to be material to an investor; (ii) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Documents is continuing, each of which will be issued in the form of a press release; (iii) there has not been any other specified default by the Company under NP 12-203, and, except as set forth below, no such other default is anticipated; (iv) the Company is not subject to any insolvency proceedings; and (v) there is no material information concerning the affairs of the Company that has not been generally disclosed.

Keep reading...Show less

Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care

Gilead Will Provide $4.5 Million in Funding to Help Improve Health Outcomes for Black Americans in the Southern United States –

– Investment Reflects Gilead's Broad and Ongoing Commitment to Advancing Health Equity –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Experience the JUVÉDERM® Difference with Allergan Aesthetics

Allē Double Point Promotion Encourages Consumers to See the JUVÉDERM ® Difference

Allergan Aesthetics, an ABBVie company (NYSE: ABBV), invites consumers to experience the JUVÉDERM ® difference. The JUVÉDERM ® Collection of Fillers is the number one selling collection of dermal fillers on the market and offers the largest portfolio of fillers specifically designed for different areas of the face to address key patient concerns, enabling a customized treatment approach. 1 Injectable dermal fillers are highly sought-after treatments among consumers who are looking to address key signs of aging or to simply accentuate what is already naturally theirs.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio

Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb.

"Turning Point has distinguished itself in the field of precision oncology, and this acquisition will further strengthen our leading oncology franchise," said Elizabeth Mily, Executive Vice President, Strategy & Business Development, Bristol Myers Squibb. "With Turning Point's lead asset, repotrectinib, Bristol Myers Squibb will be positioned to address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients. We look forward to bringing this promising, innovative medicine to patients in the second half of 2023."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the receipt of merger control clearance from the Federal Cartel Office of Germany ("FCO"), in connection with the previously announced offer (the "Offer") to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share in an all-cash transaction for total consideration of approximately $4.1 billion. The expiration of the HSR Act waiting period occurred at 11:59 p.m. Eastern Time on August 15, 2022, and the FCO clearance was received on August 15, 2022. The Offer expired at 5:00 p.m. Eastern Time on August 15, 2022 (the "Expiration Time"), and the Offer was not extended.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005404/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead to Acquire Remaining Worldwide Rights of Trodelvy®

Gilead will Assume Responsibility for Clinical Development and Commercialization in Greater China and South Korea, among Other Asian Markets –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy ® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×